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Abstract 
Background:  Limited information is available on whether antipsychotics prescribed in pregnancy are 
associated with increased risks of adverse outcomes. 
Methods: We used electronic health records from pregnant women and their children to examine 
risks of adverse maternal and child outcomes in three cohorts of women who: (A) received 
antipsychotic treatment in pregnancy (n = 416) (B) discontinued antipsychotic treatment before 
pregnancy (n = 670), and (C) had no records of antipsychotic treatment before or during pregnancy 
(n = 318,434). Absolute and risk ratios were estimated and adjusted for health and lifestyle and 
concomitant medications.  
Results: Caesarean section was more common in cohort A (25%) than C (18%), but non-significant 
after adjustment for health and lifestyle factors (Risk Ratio (adj.) 1.09 (95% CI: 0.92, 1.30). 
Proportion of gestational diabetes was similar in cohort A (2.6%) and B (2.7%), but lower in A than B 
after adjustments (RRadj: 0.43 (0.20, 0.93). Premature birth/low birthweight were more common in 
cohort A (10%) than B (4.3%) and C (3.9%), A versus B (RRadj: 2.04 (1.13, 3,67), A versus C (RRadj: 
1.43 (0.99, 2.05). Major congenital malformations were more common in A (3.4%), than B (2.2%) and 
C (2%). However no significant difference was observed (A versus B: RRadj: 1.79 (0.72, 4.47) A versus 
C RRadj: 1.59 (0.84, 3.00)). Risk estimates were similar for women prescribed atypical and typical 
antipsychotics.  
Conclusions: Antipsychotic treatment in pregnancy carries limited risks of adverse pregnancy and 
birth outcomes once adjustments have been made for health and lifestyle factors. 
  
1. Introduction 
Antipsychotics are increasingly prescribed for schizophrenia, bipolar disorder and severe depression 
in women of child bearing potential (Hayes et al., 2011; Marston et al., 2014; Prah et al., 2012; 
Verdoux et al., 2010) as well as in pregnancy (Margulis et al., 2014; Petersen et al., 2014; Toh et al., 
2013). However, no psychotropic medication has been licenced for use in pregnancy and the 2014 
National Institute for Health and Care Excellence (NICE) guidelines on antenatal and postnatal 
mental health emphasised that there are limited data on the safety of the use of these drugs in 
pregnancy and the postnatal period.(National Institute for Health and Care Excellence (NICE), 2014) 
This leaves women and their health care professionals in a treatment dilemma as they strive to 
balance all aspects of the mother’s health as well as that of the unborn child.  
In this study we used electronic health records from United Kingdom to examine potential adverse 
effects of antipsychotic medication prescribed in pregnancy on maternal and child outcome before 
and after adjustment for a range of health and lifestyle factors as well as concomitant psychotropic 
medication. We compare women who received antipsychotic prescriptions in pregnancy against 
women who discontinued treatment before pregnancy as well as women not receiving 
antipsychotics.    
2. Methods  
We used data from two electronic health records data sources, The Health Improvement Network 
(THIN) and the Clinical Practice Research Datalink (CPRD). These are large primary care databases 
that provide anonymised longitudinal general practice (family practice) data on patients’ clinical and 
prescribing records and include data from around 10% of the United Kingdom population. Diagnoses 
and symptoms are recorded by practice staff using Read codes, which is a hierarchical coding system 
including more than 100,000 codes.(Chisholm, 1990; Davé and Petersen, 2009) The Read code 
system can be mapped to ICD-10, but in addition the Read codes include a number of symptoms and 
administrative codes.(Davé and Petersen, 2009) Information on weight, height, smoking habits, 
alcohol intake and illicit drug problems is also recorded as well as information on antenatal care and 
birth details, pregnancy outcomes and postnatal care. Prescriptions are issued electronically and 
directly recorded on the general practice computer systems. In addition, the databases holds 
individual patient level information about year of birth (month of birth for individuals below 15 years 
of age), date of registration, dates of death and transfer out of the practice. There is also a 
household identifier, which is the same for individuals who are registered with the same practice 
and live in the same household.  
Over 98% of the UK population are registered with a general practitioner (GP, family doctor) (Lis and 
Mann, 1995) and the databases are broadly representative of the United Kingdom population.(Blak 
et al., 2011; Williams et al., 2012) However, Blak et al. demonstrated that THIN contained slightly 
more patients who lived in the most affluent areas.(Blak et al., 2011) While antenatal care is often 
shared between general practice staff and midwives, the GP remains responsible for women’s 
general medical care during pregnancy including prescribing of medicines.  Some women with 
psychosis also receive care from local National Health Service (NHS) mental health trusts, but most 
trusts have limited prescribing budgets and for most women prescribing of psychotropic medication 
remains with the GP during pregnancy and hence this information is available in THIN and CPRD.   
During the late 1980’s general practices started using computer systems for recording of 
consultations and patient managements and from the mid 1990’s an increasing number became 
fully computerised. (Horsfall et al., 2013) In this study we utilised data from 1st January 1995 or 
when general practices met data quality standards.(Horsfall et al., 2013; Maguire et al., 2009; 
Williams et al., 2012) 
Pregnancy and mother-child cohorts 
We created a cohort of pregnant women using data from THIN for the period 1 January 1995 to 31 
December 2012. We subsequently linked the pregnant women’s clinical records to those of a child 
with the same household identifier if they were registered with the same general practice within six 
months after they were born. Our pregnancy cohort was based on the: recorded date of delivery of 
the women; antenatal records, postnatal care records; the first day of last menstrual period (LMP); 
the estimated delivery dates (EDD). A very small proportion (1%) of the pregnancy cohort was 
identified from LMP and antenatal records alone. In order to increase the sample sizes of the cohorts 
of women who were prescribed antipsychotics before and during pregnancy we combined records 
from THIN and CPRD. Some practices contributed data to both databases and therefore we de-
duplicated the records as described by Cai et al.(Cai et al., 2010) 
 
Cohorts 
We defined three sub-cohorts based on antipsychotic prescriptions. Cohort A contained women 
with records of antipsychotic treatments two years before start of pregnancy  and with records of 
antipsychotic treatment issued between 31 and 105 days (inclusive) after the start of pregnancy  
(covering the critical period for many major congenital malformations)). Cohort B contained women 
with records of antipsychotic treatment in the two years before start of pregnancy, but no 
prescriptions issued after four weeks prior to pregnancy start. Cohort C contained women with no 
records of antipsychotic treatment in the two years before the start of pregnancy and through to the 
delivery date. Start of pregnancy was defined as the first day of LMP or 280 days before delivery if 
no records suggested a different duration of pregnancy.  
To examine maternal outcomes we used the cohorts of pregnant women, while for the child 
outcomes we used the linked mother-child cohorts which were subsets of the pregnant cohorts 
including between 65 – 75% of the pregnancies. For one child outcome, adverse birth outcome (see 
below) we replaced cohort A with a cohort of 322 women who received antipsychotic prescriptions 
in the last trimester of pregnancy as this is a more relevant risk period for these outcomes. Of these, 
274 met the criteria for the original cohort A.  
Antipsychotics 
We used all antipsychotics listed in British National Formulary (BNF) 
(https://www.medicinescomplete.com/about/publications.htm) chapter 4.2.1 except 
prochlorperazine which is primarily prescribed for ‘morning sickness’ in pregnancy. Appendix 1 
includes the names of the relevant antipsychotics.  
Outcomes 
Following maternal outcomes were examined: pre-eclampsia, gestational hypertension, gestational 
diabetes, perinatal death, and caesarean section. These are all outcomes that have previously been 
examined in association with exposure to psychotropic medication in pregnancy (Coughlin et al., 
2015; Reis and Källén, 2008). We included the following child outcomes: major congenital 
malformations, prematurity, low Apgar score (less than 7), low birth weight (less than 2500 g), , 
tremor, agitation, any breathing problems and problems with the infants’ muscle tone. We 
combined prematurity and, low birth weight into one composite outcome which we refer to 
premature/low birth weight outcome and tremor, agitation, breathing and muscle tone problems, 
low Apgar score into a second composite outcome, which we refer to as adverse  birth outcomes. 
This was done for several reasons. First, from a mother’s (and health care professional’s) perspective 
these outcomes are all signs of adverse birth outcomes and as they are all equally relevant, there is 
no obvious choice of one over the other as a primary outcome. Further, the clinical decision to stop 
psychotropic medication in pregnancy is often based on a general uncertainty about adverse effects 
rather than the risks of specific adverse outcomes.(Nordeng et al., 2010; Petersen et al., 2015) 
Finally, the use of composite outcomes reduces the number of statistical tests and may improve the 
statistical power of the study, albeit with the potential disadvantage that results relate to a cluster of 
outcomes that make up the composite outcome, and cannot be extrapolated to the individual 
components.(Freemantle et al., 2003)  
Covariates 
We extracted information from the women’s electronic health records on: age at delivery, calendar 
year of delivery, obesity (body mass index of 30 or above recorded in the year before LMP, but not in 
pregnancy), illicit drug use, alcohol problem, smoking status, pre-existing medical conditions 
(depression, epilepsy, psychosis, hypertension, diabetes), prescriptions of concomitant medication 
listed in the BNF chapter 4 including antidepressants, anxiolytics, hypnotics, anticonvulsant mood 
stabilisers and lithium. As our data are clinical data and records of illicit drug use, alcohol problems 
and smoking status are not entered on regular basis we considered records made up to three years 
before LMP or in pregnancy.  
Data analysis 
We tabulated characteristics of the women and the outcomes for each of the cohorts A, B and C and 
where there were more than five events we tabulated the numbers, absolute risks and risk 
difference with 95% confidence intervals. We estimated relative risk ratios using Poisson regression. 
Comparisons were made between cohort A (women who had continued antipsychotic medication in 
the first part of pregnancy) and cohort B (women who had discontinued treatment before 
pregnancy) using the latter as reference category. Likewise, comparisons were made between 
cohort A and cohort C (women who had not been treated with antipsychotic medication) using the 
latter as reference category. In addition we stratified the cohorts on typical and atypical 
antipsychotics and estimated the absolute risks and risk differences, but as number of events for 
several outcomes were small we did not estimate relative risks. 
Ethics 
The scheme for THIN to obtain and provide anonymous patient data was approved by the National 
Health Service South-East Multicenter Research Ethics Committee (MREC) in 2002 and the CPRD has 
been granted Multiple Research Ethics Committee approval (05/MRE04/87) to undertake purely 
observational studies. Scientific approval for this study was obtained from CSD Medical Research's 
Scientific Review Committee and scientific approval for use of CPRD data was obtained from ISAC 
(protocol number 14_087R).   
3. Results 
In total, 319,520 women were included in the study. Of these, 416 received antipsychotic treatment 
in pregnancy and 670 received antipsychotics treatment before, but not in pregnancy (Table 1). The 
mean age of women who were prescribed antipsychotics in pregnancy (Cohort A) was 32 years 
compared to 30 years cohort B and C (Table 1). A higher proportion of women who continued 
antipsychotics in pregnancy (Cohort A) as well as those who discontinued (Cohort B) had records of 
illicit drug use, alcohol problems, smoking and obesity than women not on treatment (Cohort C). 
Hence, of the women in Cohort A 14% and 8% in Cohort B had a previous record of illicit drug use in 
contrast to 0.6% of women in Cohort C. For obesity the figures were 17% in cohort A and 12% in 
cohort B versus 6.5% in cohort C (Table 1). More than 1 in 5 women who continued atypical 
antipsychotics in pregnancy were obese, far more than women on typical antipsychotics (Table 1).  
Many women who continued antipsychotics in pregnancy were also prescribed other medications 
listed in BNF chapter 4. Thus, 57% also received antidepressant and 11% anticonvulsant treatment. 
In contrast less than 2% of the women in cohort C received antidepressants and less than 0.5% 
received anticonvulsant mood stabilisers.  
The characteristics of women in the mother-child cohorts varied slightly from the distribution in the 
pregnancy cohorts (Table 2). More girls (54.5%) than boys (45.5%) were born to women in cohort A 
compared to cohort B and C (Table 2).   
Women in cohort A were more likely to deliver by caesarean section (25% (104/416)) than women in 
cohort C (18% (58,532/318,434)) (Table 3a), but after adjustment for medication use and health and 
lifestyle factors there were no significant difference (Risk Ratio (adj.) 1.09 (95% CI 0.92 to 1.30) 
(Table 4). There was no difference in the risk of delivering by caesarean section between cohort A 
and B (table 4) and after adjustments, women in cohort A were at lower risk of developing 
gestational diabetes than women in cohort B (Risk Ratio (adj.): 0.43 (95% CI 0.20 to 0.93) (Table 4). 
Notably in this analysis, obesity was strongly associated with gestational diabetes (Risk Ratio (adj.) 
5.49 (95% CI 2.67 to 11.2) (Table 4).   
Ten out of 290 (3.4%) women prescribed antipsychotics in pregnancy (cohort A) gave birth to a child 
with a major congenital malformations in comparison to 2.2% in cohort B, and 2.1% in cohort C 
(Table 3a), but the associations were not statistically significant (A vs B, Risk Ratio (adj) 1.79 (95% CI 
0.72 to 4.47); A vs C, Risk Ratio (adj) 1.59 95% CI 0.84 to 3.00)).  Children of women prescribed 
antipsychotics in pregnancy (cohort A) were more than twice as likely to experience premature 
birth/low birth weight than children of women in both cohort B and C (Table 3a and 5). The risk 
attenuated after adjustments, but there remained a significant difference between cohort A and B 
(Risk Ratio adj 2.04 (95% CI 1.13 to 3,67) and borderline difference between cohort A and C (Risk 
Ratio adj 1.43 (95% CI 0.99 to 2.05) (Table 5). 
Fourteen out of 233 (6%) women prescribed antipsychotics in the third trimester of pregnancy 
(cohort A) gave birth to a child which experienced an adverse birth outcome (tremor, agitation, 
breathing and muscle tone problems, low Apgar score) in comparison 4.7% in cohort B and 2.5% in 
cohort C. However, after adjustments for concomitant medication use and health and lifestyle 
factors there were no statistically significant difference (Table 5).   
There were no marked differences in the absolute risks and risk differences for women who received 
typical or atypical antipsychotics (Table 3b and 3c).  
4. Discussion  
Women prescribed antipsychotics in pregnancy (cohort A) were at higher risks of giving birth by 
caesarean section and to experience adverse birth outcomes than women not prescribed 
antipsychotics (cohort C). The effects attenuated after adjustment for health and lifestyle factors 
and concomitant medication and were no longer statistically significant.  Children of women 
prescribed antipsychotics in pregnancy (cohort A) were more than twice as likely to experience 
premature birth/low birth weight compared to children of women in both cohort B and C. This risk 
attenuated, but remained elevated after adjustments.  
The prevalence of gestational diabetes was similar among women from cohort A and B. However, 
there was a 3 to 5-fold increased risk among obese women irrespectively of antipsychotic treatment 
in pregnancy. Once adjustments were made for obesity, women who continued treatment in 
pregnancy (cohort A) had less of a risk of gestational diabetes than women who discontinued 
treatment before pregnancy (cohort B).  
A major strength of our study is the comparative cohort design allowing for examination of a range 
of outcomes in women of different exposure status. A limitation of our study is that exposure status 
was based on prescription data, hence it is possible that some women would not have taken 
antipsychotic treatment in pregnancy although they were prescribed the medication, this would lead 
to a bias towards the null.   
Previous research on antipsychotic treatment in pregnancy includes pharmacovigilance studies from 
drug companies’ safety databases (Brunner et al., 2013; Goldstein et al., 2000) as well as cohort 
studies based on various data sources.(Boden et al., 2012; Diav-Citrin et al., 2005; Habermann et al., 
2013; Kallen et al., 2013; Kulkarni et al., 2014; Lin et al., 2010; McKenna et al., 2005; Munk et al., 
2005; Newham et al., 2008; Sadowski et al., 2013) A review published in 2009 on the use and safety 
of individual antipsychotics prescribed in pregnancy found no definite associations between 
antipsychotic use during pregnancy and adverse perinatal outcomes.(Einarson and Boskovic, 2009) 
The review highlighted, however, the occurrence of weight gain in women on atypical 
antipsychotics;  a risk factor for both hypertension and diabetes which in turn  exert their own risk 
on pregnancy outcomes.(Anderson et al., 2005; Henderson, 2007)  Our findings suggest that the risks 
of gestational diabetes may operate via obesity in women treated with antipsychotics both before 
and during pregnancy, but our study was not designed to evaluate whether antipsychotics have a 
direct impact on weight gain during pregnancy.   
A recent review suggested that women requiring antipsychotic treatment during pregnancy have a 
higher risk of adverse birth outcomes although most studies in the review made limited adjustment 
for potential confounding.(Coughlin et al., 2015) A Canadian study sought to account for 
confounding by matching treated and un-treated women on a range of factors and as a result found 
no differences .(Vigod et al., 2015) 
Our study results are similar to a Swedish birth register study on women who reported 
antipsychotics use in early pregnancy. (Reis and Källén, 2008) Thus, the Swedish study reported an 
elevated risk of preterm birth (Odds Ratios: 1.73 (95% CI 1.31 to 2.29) and low birth weight (OR: 1.67 
(95% CI 1.21–2.29)). Initially the study also found a significant association between antipsychotic 
exposure in pregnancy and severe congenital malformations (OR 1.52 (95% CI 1.05 to 2.19)) mainly 
due to cardiovascular defects (atrium or ventricular septum defects), but after exclusion of women 
exposed to concomitant anticonvulsant medication, the odds ratio attenuated and was no longer 
statistically significant.(Reis and Källén, 2008)  
Risks of extrapyramidal and withdrawal syndromes associated with third trimester exposure of first 
generation antipsychotics have long been recognised (Falterman and Richardson, 1980) and the US 
Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency 
(MHRA) updated their advice on the risks of extrapyramidal and withdrawal syndromes in 
2011.(“Antipsychotics: risk of extrapyramidal effects or withdrawal symptoms in newborns Drug 
Safety Update - GOV.UK,” n.d.) Our estimates of adverse pregnancy outcomes attenuated 
substantially after adjustment for concomitant medication, health and life style factors. Likewise, 
Vigod et al. observed a seven-fold increased risk for neonatal adaptation syndrome, but this was 
reduced to a small non-significant relative risk in a matched cohort analysis, suggesting that the 
observed patterns may be due to confounding by concomitant medication use as well as other 
factors such as alcohol and substance misuse.(Vigod et al., 2015)  Like others we also observed a 
high prevalence of smokers and individuals with illicit drug problems as well as other factors that 
may have an inverse impact on pregnancy outcomes.(Taylor et al., 2015)  
5. Conclusions 
Women receiving antipsychotic treatment in pregnancy are of higher risk of a range of adverse 
pregnancy outcomes. Except from low birth weight/premature birth, our results suggest that rather 
than being specific associations/effects with antipsychotics, these increased risks may be associated 
with other health and lifestyle factors which are more common in this group of women. These 
include greater levels of obesity, smoking, alcohol problems, concomitant medication and illicit drug 
use. It may therefore be counterproductive to discontinue antipsychotic treatment in pregnancy 
where such treatment is judged to carry important benefits for the mental health of the mother.   
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Table 1 Characteristics of women prescribed antipsychotics in pregnancy (Cohort A) versus women who discontinued (Cohort 
B) and women not prescribed antipsychotics (Cohort C) 
  
Typical 
antipsychotics 
 
Atypical 
antipsychotics 
 All antipsychotics No antipsychotics 
Cohort A (%) B (%) A (%) B (%) A (%) B (%) C (%) 
Total 157 (100) 406 (100) 280 (100) 302 (100) 416 (100) 670 (100) 318,434 (100) 
Age (years)                             
Mean (SD) 32 (5.8) 30 (5.7) 32 (5.7) 30 (6.1) 32 (5.8) 30 (5.9) 30 (5.9) 
12-19 0 (0) 10 (2.5) 0 (0) 12 (4) 0 (0) 21 (3.1) 14,004 (4.4) 
20(29 49 (31.2) 185 (45.6) 91 (32.5) 128 (42.4) 136 (32.7) 291 (43.4) 123,704 (38.8) 
30(39 91 (58) 196 (48.3) 163 (58.2) 144 (47.7) 238 (57.2) 326 (48.7) 165,353 (51.9) 
40(49 17 (10.8) 15 (3.7) 26 (9.3) 18 (6 42 (10.1) 32 (4.8) 15,373 (4.8) 
Year                             
1995(1999 14 (8.9) 42 (10.3) 1 (0.4) 1 (0.3) 14 (3.4) 42 (6.3) 46,548 (14.6) 
2000(2004 49 (31.2) 161 (39.7) 19 (6.8) 31 (10.3) 63 (15.1) 184 (27.5) 80,542 (25.3) 
2005(2009 50 (31.8) 132 (32.5) 78 (27.9) 115 (38.1) 120 (28.8) 232 (34.6) 99,765 (31.3) 
2010(2012 44 (28) 71 (17.5) 182 (65) 155 (51.3) 219 (52.6) 212 (31.6) 91,579 (28.8) 
Lifestyle variables                             
Smoker 66 (42) 164 (40.4) 141 (50.4) 110 (36.4) 195 (46.9) 254 (37.9) 62,746 (19.7) 
Illicit drug use 21 (13.4) 39 (9.6) 37 (13.2) 23 (7.6) 56 (13.5) 56 (8.4) 2,002 (0.6) 
Alcohol problems 12 (7.6) 21 (5.2) 19 (6.8) 21 (7) 29 (7) 37 (5.5) 1,624 (0.5) 
Obesity 18 (11.5) 40 (9.9) 60 (21.4) 46 (15.2) 72 (17.3) 77 (11.5) 20,554 (6.5) 
BMI                             
Mean (SD) 28 (7.3) 27 (6.7) 29 (6.2) 28 (6.8) 28 (6.5) 27 (6.8) 26 (6.3) 
Missing 105 (66.9) 276 (68) 146 (52.1) 187 (61.9) 241 (57.9) 443 (66.1) 232,039 (72.9) 
Use of psychiatric drugs 
during exposure period A 
                      
  
    
Anticonvulsant mood 
stabilisers 
14 (8.9) 9 (2.2) 32 (11.4) 9 (3) 44 (10.6) 15 (2.2) 1,305 (0.4) 
Lithium 2 (1.3) 2 (0.5) 12 (4.3) 2 (0.7) 13 (3.1) 4 (0.6) 11 (0) 
Antipsychotics 157 (100) 0 0 280 (100) 0 (0) 416 (100) 0 (1) 0 (0) 
Antidepressants 90 (57.3) 82 (20.2) 163 (58.2) 79 (26.2) 238 (57.2) 150 (22.4) 5942 (1.9) 
Anxiolytics 17 (10.8) 23 (5.7) 34 (12.1) 13 (4.3) 48 (11.5) 33 (4.9) 805 (0.3) 
Hypnotics 29 (18.5) 20 (4.9) 41 (14.6) 17 (5.6) 63 (15.1) 32 (4.8) 598 (0.2) 
Pre(existing medical 
conditions 
                            
Depression 39 (24.8) 134 (33 69 (24.6) 97 (32.1) 105 (25.2) 217 (32.4) 20,374 (6.4) 
Epilepsy 10 (6.4) 21 (5.2) 21 (7.5) 10 (3.3) 31 (7.5) 30 (4.5) 4,846 (1.5) 
SMI 85 (54.1) 87 (21.4) 183 (65.4) 137 (45.4) 250 (60.1) 204 (30.4) 1,480 (0.5) 
Pre(existing hypertension 28 (17.8) 42 (10.3) 34 (12.1) 28 (9.3) 57 (13.7) 66 (9.9) 26,232 (8.2) 
Pre(existing diabetes 3 (1.9) 7 (1.7) 7 (2.5) 3 (1) 9 (2.2) 9 (1.3) 2,762 (0.9) 
 
   
   
  
Table 2 Characteristics of women in the mother-child cohort prescribed antipsychotics in pregnancy (Cohort A) versus 
women who discontinued (Cohort B) and women not prescribed antipsychotics (Cohort C) 
  Typical antipsychotics  
Atypical 
antipsychotics 
 All antipsychotics 
No 
antipsychotics 
Cohort A (%) B (%) A (%) B (%) A (%) B (%) C (%) 
Total 102  292  203  230  290  492  210,966  
Age (years)                             
Mean (SD) 32 (5.8) 30 (5.5) 32 (5.5) 30 (6.1) 32 (5.6) 30 (5.7) 30 (5.9) 
12-19 0 (0) 5 (1.7) 0 (0) 8 (3.5) 0 (0) 12 (2.4) 8,955 (4.2) 
20(29 32 (31.4) 140 (47.9) 63 (31) 99 (43) 92 (31.7) 222 (45.1) 80,491 (38.2) 
30(39 59 (57.8) 138 (47.3) 119 (58.6) 110 (47.8) 166 (57.2) 236 (48) 110,839 (52.5) 
40(49 11 (10.8) 9 (3.1) 21 (10.3) 13 (5.7) 32 (11) 22 (4.5) 10,681 (5.1) 
Year                             
1995(1999 9 (8.8) 25 (8.6) 1 (0.5) 0 (0) 9 (3.1) 25 (5.1) 13,339 (6.3) 
2000(2004 30 (29.4) 119 (40.8) 13 (6.4) 22 (9.6) 40 (13.8) 134 (27.2) 46,707 (22.1) 
2005(2009 32 (31.4) 99 (33.9) 57 (28.1) 85 (37) 82 (28.3) 173 (35.2) 77,626 (36.8) 
2010(2012 31 (30.4) 49 (16.8) 132 (65) 123 (53.5) 159 (54.8) 160 (32.5) 73,294 (34.7) 
Lifestyle variables                             
Smoker 51 (50) 120 (41.1) 99 (48.8) 77 (33.5) 139 (47.9) 183 (37.2) 42,502 (20.1) 
Illicit drug use 15 (14.7) 27 (9.2) 24 (11.8) 17 (7.4) 37 (12.8) 40 (8.1) 1,354 (0.6) 
Alcohol problems 10 (9.8) 16 (5.5) 15 (7.4) 17 (7.4) 23 (7.9) 28 (5.7) 1,124 (0.5) 
Obesity 11 (10.8) 31 (10.6) 45 (22.2) 38 (16.5) 53 (18.3) 62 (12.6) 15,363 (7.3) 
BMI                             
Mean (SD) 28 (7.6) 27 (6.9) 29 (6.3) 28 (6.7) 28 (6.7) 27 (6.8) 26 (6.4) 
Missing 67 (65.7) 192 (65.8) 105 (51.7) 139 (60.4) 164 (56.6) 315 (64) 148,897 (70.6) 
Use of psychiatric drugs 
during exposure period 
A                             
Antiepileptics 8 (7.8) 8 (2.7) 21 (10.3) 9 (3.9) 27 (9.3) 14 (2.8) 887 (0.4) 
Lithium 1 (1) 1 (0.3) 10 (4.9) 1 (0.4) 11 (3.8) 2 (0.4) 7 (0) 
Antipsychotics 102 (100) 0 (0) 203 (100) 0 (0) 290 (100) 0 (0) 0 (0) 
Antidepressants 61 (59.8) 61 (20.9) 118 (58.1) 73 (31.7) 169 (58.3) 124 (25.2) 4351 (2.1) 
Anxiolytics 12 (11.8) 14 (4.8) 21 (10.3) 13 (5.7) 31 (10.7) 24 (4.9) 523 (0.2) 
Hypnotics 19 (18.6) 16 (5.5) 26 (12.8) 17 (7.4) 41 (14.1) 28 (5.7) 423 (0.2) 
Pre(existing medical 
conditions                             
Depression 30 (29.4) 94 (32.2) 52 (25.6) 68 (29.6) 79 (27.2) 152 (30.9) 14,626 (6.9) 
Epilepsy 7 (6.9) 16 (5.5) 10 (4.9) 7 (3) 17 (5.9) 22 (4.5) 3,254 (1.5) 
SMI 57 (55.9) 63 (21.6) 135 (66.5) 96 (41.7) 180 (62.1) 144 (29.3) 882 (0.4) 
Pre(existing 
hypertension 20 (19.6) 28 (9.6) 25 (12.3) 22 (9.6) 42 (14.5) 47 (9.6) 19,570 (9.3) 
Pre(existing diabetes 2 (2) 5 (1.7) 6 (3) 2 (0.9) 7 (2.4) 6 (1.2) 2,005 (1) 
Child characteristics               
Males  
52 (51) 143 (49) 90 (44.3) 121 (52.6) 
132 (45.5) 253 (51.4) 
107,979 (51.2) 
Females 
50 (49) 149 (51) 113 (55.7) 109 (47.4) 
158 (54.5) 293 (48.6) 
102,987 (48.8) 
  
Days of child follow up, 
median(Inter Quartile 
Range) 
909 
(490, 
1595) 1,102 
(392, 
1979) 551 
(245, 
882) 638 
(303, 
1408) 
657 
(286, 
1351) 834 
(353, 
1758) 
738 
(349, 
1416) 
Days to Major Congenital 
Malformations record, 
median(IQR) 
110 
(90, 
333) 169 
(54, 
934) 43 (8, 7) 48 
(1, 
1167) 
85 
(21, 
110) 136 (33,1167) 
50 
(10, 
120) 
 
 
 
 
 Table 3a. Absolute risks and risk differences of adverse maternal and child outcomes associated with antipsychotic treatment 
in pregnancy 
 
      Absolute risk (%)   Risk Difference (95% CI) 
  A B C A vs B A vs C 
Maternal outcomes           
Total # in cohort  416 (100) 670  (100)  318,434 (100) -   -  -  - 
Pre-eclampsia 18 (4.3) 28 (4.2) 9355 (2.9) 0.1 (-2.3, 2.6) 1.4 (-0.6, 3.3) 
Gestational diabetes 
11 (2.6) 18 (2.7) 5227 (1.6) <0.1 (-2, 1.9) 1.0 (-0.5, 2.5) 
Caesarean section 104 (25) 145 (21.6) 58532 (18.4) 3.4 (-1.8, 8.6) 6.6 (2.5, 10.8) 
Perinatal death <5  <5  931 (0.3) - - - - 
Child outcomes           
Total # in cohort  290 (100)  492 (100)  210966 (100) -   -  -  - 
Major congenital malformations 10 (3.4) 11 (2.2) 4162 (2) 1.2 (-1.3, 3.7) 1.5 (-0.6, 3.6) 
Premature/low birth weight outcome 29 (10) 21 (4.3) 8319 (3.9) 5.7 (1.8, 9.6) 6.1 (2.6, 9.5) 
Adverse birth outcome** 14 (6) 23 (4.7) 5290 (2.5) 1.3 (-2.2, 4.9) 3.5 (0.4, 6.6) 
* Cohort A: Women prescribed antipsychotics in pregnancy, B: Women who discontinued antipsychotics before pregnancy, 
C: Women who were not on antipsychotic treatment. 
**For this outcome cohort A comprises women prescribed antipsychotics in third trimester (N = 233) 
  
Table 3b Absolute risks and risk differences of adverse maternal and child outcomes associated with typical antipsychotic 
treatment in pregnancy 
      Absolute risk (%)   Risk Difference (95% CI) 
  A B C A vs B A vs C 
Maternal outcomes                     
Total # in cohort 157 (100) 406 (100) 318434 (100)     
Pre-eclampsia 8 (5.1) 17 (4.2) 9355 (2.9) 0.9 (-3, 4.9) 2.2 (-1.3, 5.6) 
Gestational diabetes <5  8 (2) 5227 (1.6) - - - - 
Caesarean section 42 (26.8) 85 (20.9) 58532 (18.4) 5.8 (-2.2, 13.8) 8.4 (1.4, 15.3) 
Perinatal death <5  <5  931 (0.3) - - - - 
Child outcomes                      
Total # in cohort 102 (100) 292 (100) 210,966 (100)     
MCM <5  8 (2.7) 4162 (2) - - - - 
Premature/low birth weight outcome 12 (11.8) 14 (4.8) 8319 (3.9) 7 (0.3, 13.7) 7.8 (1.6, 14.1) 
Adverse birth outcome** 5 (6.1) 14 (4.8) 5290 (2.5) 1.3 (-4.4, 7) 3.6 (-1.6, 8.8) 
* Cohort A: Women prescribed typical antipsychotics in pregnancy, B: Women who discontinued typical antipsychotics before 
pregnancy, C: Women who were not on antipsychotic treatment. 
**For this outcome cohort A comprises women prescribed typical antipsychotics in third trimester 
  
Table 3c Absolute risks and risk differences of adverse maternal and child outcomes associated with atypical antipsychotic 
treatment in pregnancy 
      Absolute risk (%)   
Risk Difference (95% confidence 
interval) 
  A B C A vs B A vs C 
Maternal outcomes                     
Total # in cohort 280 (100) 302 (100) 318,434 (100)     
Pre-eclampsia 12 (4.3) 14 (4.6) 9355 (2.9) -0.4 (-3.7, 3) 1.3 (-1, 3.7) 
Gestational diabetes 9 (3.2) 11 (3.6) 5227 (1.6) -0.4 (-3.4, 2.5) 1.6 (-0.5, 3.6) 
Caesarean section 69 (24.6) 67 (22.2) 58532 (18.4) 2.5 (-4.4, 9.3) 6.3 (1.2, 11.3) 
Perinatal death <5  <5  931 (0.3) - - - - 
Child outcomes                      
Total # in cohort 203 (100) 230 (100) 210,966 (100)     
MCM 7 (3.4) <5  4162 (2) - - 1.5 (-1, 4) 
Premature/low birth weight outcome 17 (8.4) 9 (3.9) 8319 (3.9) 4.5 (-0.1, 9) 4.4 (0.6, 8.2) 
Adverse birth outcome** 9 (5.7) 9 (3.9) 5290 (2.5) 1.8 (-2.6, 6.2) 3.2 (-0.4, 6.9) 
* Cohort A: Women prescribed atypical antipsychotics in pregnancy, B: Women who discontinued atypical antipsychotics before 
pregnancy, C: Women who were not on antipsychotic treatment. 
**For this outcome cohort A comprises women prescribed atypical antipsychotics in third trimester 
 
  
 Table 4 Relative risks of adverse pregnancy outcomes associated with antipsychotic treatment in pregnancy. Results from 
crude and adjusted Poisson regression models 
  
Relative risk ratios 
(95% CI) 
P values 
Relative risk ratios 
(95% CI) 
P values 
Cohort comparisons A vs. B A vs. C 
Pre-eclampsia 1.03 (0.57, 1.87) 0.908 1.47 (0.92, 2.33) 0.100 
Pre-eclampsia (adjusted) 0.69 (0.37, 1.29) 0.248 1.24 (0.79, 1.96) 0.342 
 Age (tertiles)       
1 1   1   
2 1.11 (0.54, 2.30)  0.99 (0.94, 1.04)  
3 1.17 (0.55, 2.47)  1.19 (1.13, 1.24)  
Obesity 2.37 (1.27, 4.41)  1.92 (1.80, 2.06)  
Alcohol problems 1.27 (0.43, 3.74)  0.77 (0.56, 1.07)  
Smoker 0.92 (0.52, 1.63)  0.83 (0.78, .880)  
Illicit drug use 1.49 (0.68, 3.28)  0.94 (0.72, 1.22)  
Antidepressants 2.26 (1.19, 4.29)  1.20 (1.05, 1.37)  
Anticonvulsants 1.02 (0.35, 2.98)  1.13 (0.85, 1.51)  
Gestational diabetes 0.98 (0.46, 2.08) 0.966 1.61 (0.89, 2.91) 0.114 
Gestational diabetes 
(adjusted) 
0.43 (0.20, 0.93) 0.032 0.95 (0.53, 1.69) 0.867 
Age (tertiles)       
1 1   1   
2 2.17 (0.71, 6.61)  1.59 (1.48, 1.71)  
3 3.17 (1.01, 9.90)  2.46 (2.30, 2.64)  
Obesity 5.49 (2.67, 11.2)  3.32 (3.08, 3.57)  
Alcohol problems 0.50 (0.07, 3.56)  0.92 (0.61, 1.37)  
Smoker 1.39 (0.64, 3.02)  0.86 (0.80, .930)  
Illicit drug use - -  1.21 (0.87, 1.67)  
Antidepressants 3.73 (1.75, 7.96)  1.51 (1.29, 1.75)  
Anticonvulsants 1.54 (0.53, 4.45)  0.96 (0.65, 1.42)  
Caesarean section 1.15 (0.89, 1.48) 0.261 1.36 (1.12, 1.64) 0.001 
Caesarean section 
(adjusted) 
1.05 (0.82, 1.34) 0.671 1.09 (0.92, 1.30) 0.278 
Age (tertiles)       
1 1   1   
2 1.23 (0.89, 1.68)  1.32 (1.29, 1.34)  
3 1.79 (1.34, 2.40)  1.67 (1.64, 1.70)  
Obesity 1.45 (1.10, 1.90)  1.55 (1.51, 1.59)  
Alcohol problems 0.97 (0.61, 1.54)  0.98 (0.88, 1.09)  
Smoker 0.99 (0.78, 1.25)  0.98 (0.96, 1.00)  
Illicit drug use 1.21 (0.85, 1.72)  0.98 (0.89, 1.08)  
Antidepressants 0.95 (0.74, 1.22)  1.16 (1.10, 1.21)  
Anticonvulsants 1.02 (0.64, 1.62)  1.17 (1.06, 1.29)  
 The adjusted models includes adjustment for age, obesity, alcohol problems, smoking, illicit drug use, and antidepressant prescribing and 
nticonvulsant mood stabilisers 
 
 
  
Table 5 Relative risks of adverse child outcomes associated with antipsychotic treatment in pregnancy. Results from crude 
and adjusted Poisson regression models. 
 
Relative risk ratios 
(95% CI) 
P values 
Relative risk ratios 
(95% CI) 
P values 
Cohort comparisons A vs. B A vs. C 
Major Congenital Malformations 1.54 (0.65, 3.63) 0.321 1.74 (0.93, 3.25) 0.077 
Major Congenital Malformations 
(adjusted) 1.79 (0.72, 4.47) 
 
0.207 1.59 (0.84, 3.00) 
 
0.148 
Age (tertiles)       
1 1   1   
2 1.33 (0.42, 4.16)  0.92 (0.86, 1.00)  
3 1.28 (0.65, 3.63)  1.01 (0.94, 1.09)  
Obesity 0.57 (0.72, 4.47)  0.99 (0.87, 1.12)  
Alcohol problems - -  1.10 (0.75, 1.62)  
Smoker 0.14 (0.03,0.62)  1.03 (0.95, 1.11)  
Illicit drug use - -  1.03 (0.72, 1.48)  
Antidepressants 0.89 (0.37, 2.17)  1.01 (0.82, 1.24)  
Anticonvulsants - -  1.68 (1.18, 2.40)  
Premature/low birth weight outcome 2.34 (1.33, 4.10) 0.003 2.53 (1.76, 3.65) <0.001 
Premature/low birth weight outcome 
(adjusted) 2.04 (1.13, 3.67) 0.017 1.43 (0.99, 2.05) 0.052 
Age (tertiles)       
1 1   1   
2 0.98 (0.49, 1.95)  0.95 (0.90, 1.00)  
3 1.01 (0.52, 1.98)  1.03 (0.98, 1.09)  
Obesity 0.89 (0.42, 1.84)  1.13 (1.04, 1.23)  
Alcohol problems 0.41 (0.10, 1.59)  1.21 (0.97, 1.51)  
Smoker 0.99 (0.56, 1.74)  1.39 (1.33, 1.46)  
Illicit drug use 1.78 (0.89, 3.54)  1.94 (1.64, 2.29)  
Antidepressants 1.44 (0.81, 2.56)  1.55 (1.38, 1.73)  
Anticonvulsants 1.13 (0.43, 2.91)  1.37 (1.06, 1.76)  
 Adverse birth outcome** 1.28 (0.66, 2.49) 0.459 2.39 (1.41, 4.04) 0.001 
 Adverse birth outcome** (adjusted) 1.03 (0.50, 2.12) 0.927 1.46 (0.87, 2.46) 0.151 
Age (tertiles)       
1 1   1   
2 1.79 (0.80, 4.01)  0.85 (0.80, .915)  
3 1.41 (0.59, 3.36)  0.95 (0.89, 1.01)  
Obesity 1.45 (0.67, 3.11)  1.38 (1.25, 1.51)  
Alcohol problems 1.49 (0.45, 4.91)  1.41 (1.07, 1.86)  
Smoker 1.52 (0.80, 2.90)  1.24 (1.16, 1.32)  
Illicit drug use 1.01 (0.37, 2.74)  1.61 (1.26, 2.04)  
Antidepressants 0.77 (0.39, 1.54)  1.55 (1.32, 1.84)  
Anticonvulsants 4.11 (1.66, 10.1)  1.56 (1.15, 2.13)  
adjusted models includes adjustment for age, obesity, alcohol problems, smoking, illicit drug use, and antidepressant prescribing and 
anticonvulsant mood stabilisers. **For this outcome cohort A comprises women prescribed antipsychotics in third trimester 
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